SG11202107995SA - Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof - Google Patents

Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Info

Publication number
SG11202107995SA
SG11202107995SA SG11202107995SA SG11202107995SA SG11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA SG 11202107995S A SG11202107995S A SG 11202107995SA
Authority
SG
Singapore
Prior art keywords
antibodies
tnfa
specificity
methods
targeting
Prior art date
Application number
SG11202107995SA
Inventor
David Urech
Tea Gunde
Sebastian Meyer
Christian Hess
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19154852.8A external-priority patent/EP3689907A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of SG11202107995SA publication Critical patent/SG11202107995SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202107995SA 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof SG11202107995SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19154852.8A EP3689907A1 (en) 2019-01-31 2019-01-31 Antibodies targeting il-17a and methods of use thereof
EP19154850 2019-01-31
EP19154846 2019-01-31
PCT/EP2020/052481 WO2020157305A1 (en) 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202107995SA true SG11202107995SA (en) 2021-08-30

Family

ID=69192095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107995SA SG11202107995SA (en) 2019-01-31 2020-01-31 Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof

Country Status (11)

Country Link
US (1) US20220127350A1 (en)
EP (1) EP3917954A1 (en)
JP (1) JP2022523908A (en)
KR (1) KR20210122243A (en)
CN (1) CN113631574A (en)
AU (1) AU2020215795A1 (en)
CA (1) CA3127935A1 (en)
IL (1) IL284644A (en)
MA (1) MA54857A (en)
SG (1) SG11202107995SA (en)
WO (1) WO2020157305A1 (en)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
NO309690B1 (en) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonator type exploding wire for use with a perforation tool in a well
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP5089582B2 (en) 2005-06-07 2012-12-05 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー Stable soluble antibody that inhibits TNFα
DK1963368T6 (en) 2005-12-13 2020-06-29 Lilly Co Eli Anti-IL-17 ANTIBODIES
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
EP2046835B1 (en) 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP3444274B1 (en) 2008-06-25 2020-12-23 Novartis AG Stable and soluble antibodies inhibiting tnf
CN104004094B (en) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 The humanization of the rabbit antibody carried out using universal antibody framework
MX2011000009A (en) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Methods and compositions for enhanced delivery of macromolecules.
BRPI0919531A2 (en) 2008-09-29 2015-12-08 Roche Glycart Ag antibodies to human il17 and uses thereof
SG173705A1 (en) * 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
JP2013537414A (en) 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Antibodies against IL-17
US9655964B2 (en) 2011-10-24 2017-05-23 Abbvie Inc. Bispecific antibodies directed against TNF-α and IL-17
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
ES2758473T3 (en) * 2013-02-08 2020-05-05 Novartis Ag Anti-IL-17A antibodies and their use in the treatment of autoimmune and inflammatory disorders
TW201444867A (en) 2013-03-08 2014-12-01 Lilly Co Eli Anti-TNF-anti-IL-17 bispecific antibodies
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
AU2014301629B2 (en) 2013-06-26 2020-02-06 Numab Therapeutics AG Novel antibody frameworks
EP3027649B1 (en) 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
US9862765B2 (en) 2013-11-18 2018-01-09 Shanghai Hengrui Pharmaceutical Co., Ltd. IL-17A binding agent and uses thereof
RU2577228C2 (en) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Anti-il-17 antibodies, methods of their production and application
RU2609627C2 (en) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN108251431B (en) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 Double-carrier system and application thereof
CA2989474C (en) 2015-06-15 2023-09-05 Numab Innovation Ag Hetero-dimeric multi-specific antibody format
US20190330328A1 (en) 2015-10-19 2019-10-31 Christian Mann Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN105542011A (en) * 2015-11-18 2016-05-04 北京嘉泰先科医药科技有限公司 Bispecific or multispecific Ig JR binding protein
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
WO2017132457A1 (en) 2016-01-28 2017-08-03 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
KR102571700B1 (en) * 2016-03-17 2023-08-29 누맙 세러퓨틱스 아게 Anti-TNFα antibodies and functional fragments thereof
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
KR20200013230A (en) * 2017-06-05 2020-02-06 누맙 세러퓨틱스 아게 Hetero-dimeric multispecific antibody format that targets at least CD3 and HSA
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
CN109206515B (en) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 Fully human anti-human interleukin 17A antibody and application thereof

Also Published As

Publication number Publication date
IL284644A (en) 2021-08-31
CN113631574A (en) 2021-11-09
WO2020157305A1 (en) 2020-08-06
KR20210122243A (en) 2021-10-08
AU2020215795A1 (en) 2021-07-29
CA3127935A1 (en) 2020-08-06
US20220127350A1 (en) 2022-04-28
EP3917954A1 (en) 2021-12-08
JP2022523908A (en) 2022-04-27
MA54857A (en) 2021-12-08

Similar Documents

Publication Publication Date Title
EP3743063A4 (en) Inhibitors of cbl-b and methods of use thereof
EP3612551A4 (en) Variants of cpf1 (cas12a) with altered pam specificity
EP3740510A4 (en) Multispecific antigen binding proteins and methods of use thereof
IL287468A (en) Nucleic acid constructs and methods for their manufacture
EP4045643A4 (en) Variants of cas12a nucleases and methods of making and use thereof
IL277559A (en) Multispecific antibodies and use thereof
IL273841A (en) Antibodies targeting cd137 and methods of use thereof
MA44061A (en) MULTISPECIFIC ANTIBODY MOLECULES WITH SPECIFICITY FOR TNF-ALPHA, IL-17A AND IL-17F
IL291325A (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
EP3644062A4 (en) Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit
ZA202208798B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL304403A (en) Multispecific antibodies having specificity for ror1 and cd3
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
ZA202208799B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
EP3749330A4 (en) Repeat rna as biomarkers of tumor immune response
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
EP3754021A4 (en) Aptamer for sclerostin and use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL288886A (en) Antibodies and methods of use
EP3755689A4 (en) Inhibitors of egfr and methods of use thereof
EP3802525A4 (en) Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
EP3704248A4 (en) Methods and kits for targeted enrichment of target dna with high gc content